RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or
“RegeneRx”) today announced that Dr. Allan L. Goldstein, the Company’s
chairman and chief scientific advisor and emeritus professor and
chairman of biochemistry at The George Washington University School of
Medicine, will be a plenary speaker at The Drug Discovery & Therapy
World Congress 2014 in Boston, MA on Monday, June 16. Dr. Goldstein
will open the meeting with a talk entitled, “Advances in Clinical
Applications of Synthetic Thymosins in Treating Life-Threatening
Diseases.”
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of a novel therapeutic peptide,
Thymosin beta 4, for tissue and organ protection, repair and
regeneration. RegeneRx currently has three drug candidates in clinical
development for ophthalmic, cardiac and dermal indications, three
strategic licensing agreements in China, Pan Asia (Korea, Japan, and
Australia, among others) and the EU, and has an extensive worldwide
patent portfolio covering its products. The Company also has developed
several peptides that it believes may be useful improving aging skin in
the cosmeceutical field.
Forward-Looking Statements
Any statements in this press release that are not historical facts are
forward-looking statements made under the provisions of the Private
Securities Litigation Reform Act of 1995. Any forward-looking statements
made by Dr. Goldstein may involve speculation and uncertainties that may
or may not prove to be accurate and may be materially different from any
results implied by such forward-looking statements. Please view these
and other risks described in the Company’s filings with the Securities
and Exchange Commission (“SEC”), including those identified in the “Risk
Factors” section of the annual report on Form 10-K for the year ended
December 31, 2013, and subsequent quarterly reports filed on Form 10-Q,
as well as other filings it makes with the SEC. Any forward-looking
statements in this press release represent the Company’s views only as
of the date of this release and should not be relied upon as
representing its views as of any subsequent date. The Company
specifically disclaims any obligation to update this information, as a
result of future events or otherwise, except as required by applicable
law.
Copyright Business Wire 2014